373 related articles for article (PubMed ID: 23562338)
1. Digestive neuroendocrine tumors (DNET): the era of targeted therapies.
Boussaha T; Rougier P; Taieb J; Lepere C
Clin Res Hepatol Gastroenterol; 2013 Apr; 37(2):134-41. PubMed ID: 23562338
[TBL] [Abstract][Full Text] [Related]
2. Current clinical trials of targeted agents for well-differentiated neuroendocrine tumors.
Raj N; Reidy-Lagunes D
Pancreas; 2014 Nov; 43(8):1185-9. PubMed ID: 25333401
[TBL] [Abstract][Full Text] [Related]
3. Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas.
Fazio N; Cinieri S; Lorizzo K; Squadroni M; Orlando L; Spada F; Maiello E; Bodei L; Paganelli G; Delle Fave G; de Braud F
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S87-94. PubMed ID: 21129617
[TBL] [Abstract][Full Text] [Related]
4. Advances in the systemic treatment of neuroendocrine tumors in the era of molecular therapy.
Leung R; Lang B; Wong H; Chiu J; Yat WK; Shek T; Cho WY; Yau LC; Yau T
Anticancer Agents Med Chem; 2013 Mar; 13(3):382-8. PubMed ID: 23092266
[TBL] [Abstract][Full Text] [Related]
5. [Drug therapy for neuroendocrine tumours].
Tóth M
Orv Hetil; 2013 Sep; 154(39):1556-64. PubMed ID: 24058101
[TBL] [Abstract][Full Text] [Related]
6. Clinical review: Current scientific rationale for the use of somatostatin analogs and mTOR inhibitors in neuroendocrine tumor therapy.
Bousquet C; Lasfargues C; Chalabi M; Billah SM; Susini C; Vezzosi D; Caron P; Pyronnet S
J Clin Endocrinol Metab; 2012 Mar; 97(3):727-37. PubMed ID: 22170729
[TBL] [Abstract][Full Text] [Related]
7. Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors.
Naraev BG; Strosberg JR; Halfdanarson TR
Oncology; 2012; 83(3):117-27. PubMed ID: 22797357
[TBL] [Abstract][Full Text] [Related]
8. Perspectives in the development of novel treatment approaches.
Yao JC; Catena L; Colao A; Paganelli G
Tumori; 2010; 96(5):858-73. PubMed ID: 21302643
[No Abstract] [Full Text] [Related]
9. New strategies for advanced neuroendocrine tumors in the era of targeted therapy.
Dong M; Phan AT; Yao JC
Clin Cancer Res; 2012 Apr; 18(7):1830-6. PubMed ID: 22338018
[TBL] [Abstract][Full Text] [Related]
10. Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook.
Mateo J; Heymach JV; Zurita AJ
Mol Diagn Ther; 2012 Jun; 16(3):151-61. PubMed ID: 22515658
[TBL] [Abstract][Full Text] [Related]
11. Systemic therapy for advanced pancreatic neuroendocrine tumors.
Kulke MH
Semin Oncol; 2013 Feb; 40(1):75-83. PubMed ID: 23391115
[TBL] [Abstract][Full Text] [Related]
12. Recent studies show promise for treating rare pancreatic tumors.
Peres J
J Natl Cancer Inst; 2011 Apr; 103(8):624-7. PubMed ID: 21474831
[No Abstract] [Full Text] [Related]
13. New directions in the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): shifting from symptom management to targeting tumors.
Weber M
Clin Adv Hematol Oncol; 2014 Dec; 12(12 Suppl 19):12-7. PubMed ID: 25768104
[No Abstract] [Full Text] [Related]
14. Novel agents in gastroenteropancreatic neuroendocrine tumors.
Stevenson R; Libutti SK; Saif MW
JOP; 2013 Mar; 14(2):152-4. PubMed ID: 23474560
[TBL] [Abstract][Full Text] [Related]
15. Systemic Therapies for Advanced Pancreatic Neuroendocrine Tumors.
Raj N; Reidy-Lagunes D
Hematol Oncol Clin North Am; 2016 Feb; 30(1):119-33. PubMed ID: 26614372
[TBL] [Abstract][Full Text] [Related]
16. [Current status and therapeutic strategy for pancreatic neuroendocrine tumors in Japan].
Ito T; Igarashi H; Jensen RT; Takayanagi R
Fukuoka Igaku Zasshi; 2012 Jul; 103(7):131-7. PubMed ID: 22978065
[No Abstract] [Full Text] [Related]
17. New drugs in neuroendocrine tumors: rising of new therapeutic philosophies?
Eriksson B
Curr Opin Oncol; 2010 Jul; 22(4):381-6. PubMed ID: 20473165
[TBL] [Abstract][Full Text] [Related]
18. Pancreatic neuroendocrine tumors: signal pathways and targeted therapies.
Peng L; Schwarz RE
Curr Mol Med; 2013 Mar; 13(3):333-9. PubMed ID: 23331005
[TBL] [Abstract][Full Text] [Related]
19. Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours.
Yim KL
Endocrine; 2011 Oct; 40(2):181-6. PubMed ID: 21870172
[TBL] [Abstract][Full Text] [Related]
20. Progress in the treatment of neuroendocrine tumors.
Chan JA; Kulke MH
Curr Oncol Rep; 2009 May; 11(3):193-9. PubMed ID: 19336011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]